Clinical trial
A Phase 1a/1b, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GNTbm 38 in Solid Tumors and Relapsed/Refractory Peripheral T-Cell Lymphoma.
NCT07842445 is registered in ClinicalTrials.gov with Great Novel Therapeutics Biotech & Medicals Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1a/1b, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GNTbm 38 in Solid Tumors and Relapsed/Refractory Peripheral T-Cell Lymphoma.
- Lead sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- June 30, 2029
- Enrollment
- 70 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed or refractory peripheral t-cell lymphoma (ptcl), solid tumor (phase i)